October 20, 2023 Release Highlights Copied

10/20/20232023 VBCRelease note

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Advance Care Planning.

MIPS Quality Measures Dashboard

Starting Monday, Oct. 23, 2023, you can view data from Q3 2023 using the Time Period drop-down in the MIPS Quality Measures dashboard. In addition, the Practice Insights Avg Perf % column will be updated to reflect Q3 2023.

The dashboard has also been updated to reflect the below refinement(s) for:

Measure	Description
Promoting Interoperability: Query of Prescription Drug Monitoring Program (PDMP)	2023 Measure Specification Update to include: This measure is no longer a bonus measure. It is now a required measure for submission. If your patient has at least one schedule II opioid, schedule III, or IV drug electronically prescribed, they will appear in this measure. If the numerator is populated with at least one patient, the practice/clinician will receive 10 points for the measure.	Practices may see an increase in numerator and denominator due to the addition of additional drugs.
PIMSH #15: Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)	A technical refinement was made to: Include all applicable external drugs Refined search method to ensure we are pulling in all applicable drugs.	Practices will see numerator/denominator changes.
PIMSH #16: Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center	A technical refinement was made to: Include all applicable external drugs Combination therapy attributed properly when given Refined search method to ensure we are pulling in all applicable drugs.	Practices will see numerator/denominator changes.

Measure

Description

Promoting Interoperability: Query of Prescription Drug Monitoring Program (PDMP)

2023 Measure Specification Update to include:

This measure is no longer a bonus measure. It is now a required measure for submission.
If your patient has at least one schedule II opioid, schedule III, or IV drug electronically prescribed, they will appear in this measure.
If the numerator is populated with at least one patient, the practice/clinician will receive 10 points for the measure.

Practices may see an increase in numerator and denominator due to the addition of additional drugs.

PIMSH #15: Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)

A technical refinement was made to:

Include all applicable external drugs
Refined search method to ensure we are pulling in all applicable drugs.

Practices will see numerator/denominator changes.

PIMSH #16: Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center

A technical refinement was made to:

Include all applicable external drugs
Combination therapy attributed properly when given
Refined search method to ensure we are pulling in all applicable drugs.

Practices will see numerator/denominator changes.

Advance Care Planning Activity & Performance Dashboard

Starting Monday, Oct. 23, 2023, you can view data from Q3 2023 using the Time Period drop-down in the Advance Care Planning Activity & Performance dashboard. In addition, the Practice Insights Avg Perf % column will be updated to reflect Q3 2023.

Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

Measure	Description
MIPS Quality Measures Dashboard
#047	Advance Care Plan
#104	Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer
#130	Current Medications Documentation
#134	Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#144	Pain Care Plan
#226	Tobacco Screening and Cessation
#236	Controlling High Blood Pressure
#374	Closing the Referral Loop
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452	Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#453	Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 147 Days of Life (Inverse Measure)
#457	Patients Admitted to Hospice for < 3 Days
PIMSH#1	Advance Care Planning in Stage 4 Disease
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#8	Mutation Testing for Lung Cancer
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center